Obstetrics & Gynecology Email Alerts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Obstetrics & Gynecology 1997;89:1012-1016
© 1997 by The American College of Obstetricians and Gynecologists
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hempling, R.
Right arrow Articles by Mettlin, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hempling, R.
Right arrow Articles by Mettlin, C.

Articles

Hormone replacement therapy as a risk factor for epithelial ovarian cancer: results of a case-control study

RE Hempling, C Wong, MS Piver, N Natarajan, and CJ Mettlin

OBJECTIVE: To evaluate the role of hormone replacement therapy (HRT) as a risk factor for the development of epithelial ovarian cancer. METHODS: A case-control study was performed that used 491 patients with epithelial ovarian cancer frequency matched for age at diagnosis (+/-5 years) with a control population of 741 patients with malignancies of nonestrogen-dependent tissues. The odds ratio (OR) for the development of epithelial ovarian cancer was estimated using logistic regression analysis with adjustment for age at diagnosis, parity, oral contraceptive use, smoking history, family history of epithelial ovarian cancer, age at menarche, menopausal status, income, and education. RESULTS: One hundred of 491 patients (20.4%) in the study population had ever used HRT, and 160 of 741 patients (21.6%) in the control population had ever used HRT (OR 0.85; 95% confidence interval [CI] 0.62, 1.2). A significant association between HRT and specific histologic subtypes of epithelial ovarian cancer was not demonstrable for serous cystadenocarcinoma (OR 1.2, 95% CI 0.8, 1.7), Clear cell carcinoma (OR 1.1, 95% CI 0.4, 3.4), or endometrioid carcinoma (OR 0.4; 95% CI 0.2, 1.2). A significant association between duration of use of HRT and the risk of developing epithelial ovarian cancer was not demonstrable for under 5 years (OR 0.8; 95% CI 0.5, 1.2), 5-9 years (OR 0.6; 95% CI 0.3, 1.1), or 10 or more years (OR 0.6; 95% CI 0.3, 1.4). CONCLUSION: A significant association between the use of HRT and the risk of developing epithelial ovarian cancer, even with prolonged exposure, is not demonstrable.


This article has been cited by other articles:


Home page
 Hum Reprod UpdateHome page
C. M. Greiser, E. M. Greiser, and M. Doren
Menopausal hormone therapy and risk of ovarian cancer: systematic review and meta-analysis
Hum. Reprod. Update, September 1, 2007; 13(5): 453 - 463.
[Abstract] [Full Text] [PDF]

Home page
 Am J EpidemiolHome page
T. Riman, P. W. Dickman, S. Nilsson, N. Correia, H. Nordlinder, C. M. Magnusson, and I. R. Persson
Risk Factors for Invasive Epithelial Ovarian Cancer: Results from a Swedish Case-Control Study
Am. J. Epidemiol., August 15, 2002; 156(4): 363 - 373.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
J. V. Lacey Jr, P. J. Mink, J. H. Lubin, M. E. Sherman, R. Troisi, P. Hartge, A. Schatzkin, and C. Schairer
Menopausal Hormone Replacement Therapy and Risk of Ovarian Cancer
JAMA, July 17, 2002; 288(3): 334 - 341.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
T. Riman, P. W. Dickman, S. Nilsson, N. Correia, H. Nordlinder, C. M. Magnusson, E. Weiderpass, and I. R. Persson
Hormone Replacement Therapy and the Risk of Invasive Epithelial Ovarian Cancer in Swedish Women
J Natl Cancer Inst, April 3, 2002; 94(7): 497 - 504.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
V. Syed, G. Ulinski, S. C. Mok, G. K. Yiu, and S.-M. Ho
Expression of Gonadotropin Receptor and Growth Responses to Key Reproductive Hormones in Normal and Malignant Human Ovarian Surface Epithelial Cells
Cancer Res., September 1, 2001; 61(18): 6768 - 6776.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
C. Bosetti, E. Negri, S. Franceschi, D. Trichopoulos, V. Beral, C. La Vecchia, E. Hernandez, C. Rodriguez, E. E. Calle, E. J. Jacobs, et al.
Relationship Between Postmenopausal Hormone Replacement Therapy and Ovarian Cancer
JAMA, June 27, 2001; 285(24): 3089 - 3090.
[Full Text] [PDF]

Home page
 JAMAHome page
C. Rodriguez, A. V. Patel, E. E. Calle, E. J. Jacob, and M. J. Thun
Estrogen Replacement Therapy and Ovarian Cancer Mortality in a Large Prospective Study of US Women
JAMA, March 21, 2001; 285(11): 1460 - 1465.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
R. B. Ness and C. Cottreau
Possible Role of Ovarian Epithelial Inflammation in Ovarian Cancer
J Natl Cancer Inst, September 1, 1999; 91(17): 1459 - 1467.
[Abstract] [Full Text] [PDF]

Home page
 JWatch Women's HealthHome page
No Link Found Between HRT and Epithelial Ovarian Cancer
Journal Watch Women's Health, July 1, 1997; 1997(701): 8 - 8.
[Full Text]

Home page
 JWatch GeneralHome page
HORMONE REPLACEMENT THERAPY DOES NOT INCREASE THE RISK FOR EPITHELIAL OVARIAN CANCERS
Journal Watch (General), June 17, 1997; 1997(617): 4 - 4.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1997 by the American College of Obstetricians and Gynecologists.